Novo vs Lilly Over Weight Loss Ads | Business and Finance News

The weight loss drug war just hit the courtroom as Novo Nordisk sues Eli Lilly, claiming their TV ads misleadingly compare drug results—specifically, that Zepbound users lost more than Wegovy users, when Novo’s newer dose shows even better outcomes. The lawsuit also targets ads comparing Mounjaro to Ozempic, with Novo demanding corrective campaigns and damages. If the court rules in Novo’s favor, it could reshape market perception—even if the financial stakes are modest, the PR impact could be huge. With these drugs now the world’s top-selling meds, the battle for dominance is heating up fast. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cf7b76ab5fec1766